Pharmafile Logo
Pharmafocus logo
Advanced Search

lynparza

Showing 15 posts of 35 posts found.

lynparza

Europe approves Lynparza in HER2-, gBRCAm advanced breast cancer

April 10, 2019
Research and Development, Sales and Marketing AstraZeneca, Cancer, MSD, breast cancer, lynparza, pharma

Lynparza (olparib), the poly ADP ribose polymerase (PARP) inhibitor developed by AstraZeneca and MSD, has been awarded marketing approval by …

News
lynparza

Lynparza extends progression-free survival in gBRCAm metastatic pancreatic cancer

February 26, 2019
Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza, pharma

AstraZeneca and MSD have lifted the curtain on new Phase 3 data for Lynparza (olaparib), confirming that the drug generated …

News
astrazeneca-sign

AstraZeneca chalks up double Japanese approval in lung and breast cancer

July 2, 2018
Sales and Marketing AstraZeneca, Cancer, Imfinzi, NSCLD, breast cancer, lung cancer, lynparza, pharma

It’s a big step forward for AstraZeneca’s global marketing operations as the company announced that two of its products have …

News
astrazeneca_sign_sky

AZ and MSD impress at ASCO with Lynparza combo data in prostate cancer

June 5, 2018
Research and Development ASCO, AstraZeneca, Cancer, MSD< pharma, Merck, lynparza, prostate cancer

In another major ASCO reveal, AstraZeneca and partner MSD lifted the curtain at the event on new data for its …

News
credit_-_daniel_leal-olivas-afp

European approval for tablet formulation of Lynparza in ovarian cancer

May 8, 2018
Research and Development, Sales and Marketing AstraZeneca, Cancer, EMA, Europe, MSD, lynparza, ovarian cancer, pharma

AstraZeneca and MSD’s poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) has been approved for use in Europe, it has emerged, …

News
astrazeneca_sign_sky

AstraZeneca scores double approvals in Japan for asthma and ovarian cancer

January 19, 2018
Medical Communications, Sales and Marketing AstraZeneca, Cancer, Fasenra, Japan, asthma, lynparza, ovarian cancer, pharma

AstraZeneca has unveiled a double dose of approvals awarded to its medicines in Japan: Fasenra (benralizumab) has been given authorisation …

News
fda2outsideweb

AZ and MSD’s Lynparza becomes first PARP inhibitor approved in US for metastatic breast cancer

January 15, 2018
Sales and Marketing AstraZeneca, Cancer, FDA, MSD, breast cancer, lynparza, pharma

The FDA has announced that it has awarded marketing authorisation in the US to Lynparza (olaparib), a poly ADP-ribose polymerase …

News
tesaro

New PARP inhibitor hits UK market, offering distinct advantage

December 18, 2017
Sales and Marketing AstraZeneca, Novartis, Tesaro, Zejula, biotech, drugs, lynparza, pharma, pharmaceutical

Tesaro’s Zejula has been launched in the UK but availability on the NHS has still not been decided. The PARP …

News
astrazeneca_sign_sky

AZ’s Lynparza improves survival and maintains quality of life against ovarian cancer

June 2, 2017
Medical Communications, Research and Development AstraZeneca, lynparza

New Phase 3 trial data has found that AstraZeneca’s Lynparza (olaparib) provides sustained quality of life (QoL) and improved progression-free …

News
cq5dam

AZ reveals compelling PhIII data for ovarian cancer treatment

October 26, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AZ, AstraZeneca, lynparza

AstraZeneca has revealed new results from a Phase III trial investigating the efficacy of its Lynparza drug as a monotherapy …

News
clinical_trial-web

Tesaro’s ovarian cancer drug success threatens market rivals

October 12, 2016
Research and Development AbbVie, AstraZeneca, Pfizer, Roche, Tesaro, avastin, lynparza, niraparib, talazoparib, veliparib

Phase III results from Tesaro’s niraparib PARP inhibitor could spell trouble for rivals Roche and AstraZeneca as its showed sizeable …

News
astrazeneca_plaque

AstraZeneca says latest study data for Lynparza suggest improvement in overall survival in ovarian cancer

June 7, 2016
Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AstraZeneca, NHS, lynparza, ovarian cancer, regulation

UK drugmaker AstraZeneca (LSE: AZN) said mid-stage trials for Lynparza (olaparib) maintenance therapy suggest an improvement in overall survival (OS) …

News

AstraZeneca’s Lynparza fails to meet primary endpoint in Phase III gastric cancer trials

May 18, 2016
Research and Development AstraZeneca, failed to meet endpoint, gastric trail, lynparza, phase III

AstraZeneca has announced that its treatment for advanced gastric cancer, Lynparza (olaparib), failed to meet the primary endpoint of overall …

News
Lynparza

AZ’s Lynparza gets prostate cancer breakthrough status

January 28, 2016
Sales and Marketing AstraZeneca, Breakthrough Therapy Designation, FDA, lynparza, olaparib, prostate cancer

AstraZeneca’s Lynparza has been granted breakthrough therapy designation by the FDA as a monotherapy for the treatment of a specific …

News
Lynparza

NICE recommends AstraZeneca’s Lynparza after price reduction

December 11, 2015
Medical Communications, Sales and Marketing AstraZeneca, NICE, fallopian tube cancer, lynparza, olaparib, ovarian cancer, peritoneal cancer

NICE has recommended AstraZeneca’s Lynparza for maintenance treatment of relapsed ovarian, fallopian tube and peritoneal cancer. In draft guidance the …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025